CBD-Dominant Cannabis Extract Improved Multiple Symptoms in Children With Moderate to Severe Autism
A CBD-dominant extract (33:1 CBD:THC) improved communication, attention, aggression, and quality of life in 30 children with moderate to severe autism.
Quick Facts
What This Study Found
Thirty children (5-18) with moderate-severe ASD showed improvements in communication, attention, learning, eye contact, and reduced aggression. Both clinical and parental assessments confirmed improvements with minimal adverse effects.
Key Numbers
30 patients aged 5-18. CBD:THC ratio 33:1. Improvements in communication, attention, learning, eye contact. Reduced aggression. Minimal adverse effects.
How They Did This
Retrospective observational cohort of 30 ASD patients aged 5-18 treated with CBD-dominant extract (33:1 CBD:THC) at individualized doses.
Why This Research Matters
Current autism pharmacotherapy is limited. If CBD-dominant extracts safely improve core symptoms, they could fill a major treatment gap.
The Bigger Picture
Multiple observational studies suggest cannabinoid benefits in autism, but large placebo-controlled trials are still lacking.
What This Study Doesn't Tell Us
No placebo control. Retrospective. Small sample. Individualized dosing. Unblinded assessments.
Questions This Raises
- ?Would a placebo-controlled trial confirm these improvements?
- ?What is the optimal CBD:THC ratio for autism?
Trust & Context
- Key Stat:
- CBD-dominant extract improved communication, attention, and behavior in 30 children with ASD
- Evidence Grade:
- Uncontrolled observational study with small sample and no blinding.
- Study Age:
- Published in 2024.
- Original Title:
- Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 17(6) (2024)
- Authors:
- Mazza, Jeanne Alves de Souza, Ferreira, Lisiane Seguti, Martins-Vieira, Alice de Faria, Beserra, Doris Day Lopes, Rodrigues, Victor Alves, Malcher-Lopes, Renato, Caixeta, Fabio V
- Database ID:
- RTHC-05532
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can CBD help with autism?
In this study, a CBD-dominant extract improved multiple symptoms in 30 children, but the lack of placebo control means results need confirmation.
Is CBD safe for children with autism?
Minimal adverse effects were reported in this study of 30 children aged 5-18, but larger controlled trials are needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05532APA
Mazza, Jeanne Alves de Souza; Ferreira, Lisiane Seguti; Martins-Vieira, Alice de Faria; Beserra, Doris Day Lopes; Rodrigues, Victor Alves; Malcher-Lopes, Renato; Caixeta, Fabio V. (2024). Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.. Pharmaceuticals (Basel, Switzerland), 17(6). https://doi.org/10.3390/ph17060686
MLA
Mazza, Jeanne Alves de Souza, et al. "Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.." Pharmaceuticals (Basel, 2024. https://doi.org/10.3390/ph17060686
RethinkTHC
RethinkTHC Research Database. "Clinical and Family Implications of Cannabidiol (CBD)-Domina..." RTHC-05532. Retrieved from https://rethinkthc.com/research/mazza-2024-clinical-and-family-implications
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.